With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...
When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients ...
Effective compliance now spans transaction eligibility, OPAIS synchronization, Medicaid exclusion validation, cost-report ...
Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 ...
On December 29, 2025—just three days before the 340B Rebate Model Pilot Program (the Rebate Program) was set to begin—the U.S. District Court for the District of Maine issued an order granting a ...
The 340B Drug Discount Program was designed to help safety-net providers make drugs available to low-income patients and earn revenue. Drug manufacturers have put restrictions on which pharmacies ...
Minnesota's 340B drug discount program faces scrutiny as small clinics struggle and large hospitals profit, sparking ...
Nevada hospitals and clinics face challenges as drug manufacturers restrict access to a federal discount drug program, ...
A federal judge in Missouri has denied a request by AstraZeneca Pharmaceuticals LP to compel several nonparty hospitals and ...
Jacksonville Journal-Courier on MSN
Federal drug discount expansion proposal may cost Illinois millions, agency head says
Pending legislation to expand providers’ access to discounted drugs has sparked strong lobbying campaigns for and against the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results